Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-03

Clinical Trial Update: Impact of Evolocumab in Cardiac Transplant Patients With CAV [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating evolocumab in heart transplant recipients with cardiac allograft vasculopathy has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Repatha (Evolocumab)

Snippet

Sponsor: University of Nebraska | Conditions: Heart Transplant | Phase 2 | Status: COMPLETED | Results posted: 2024-06-03